Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 44 of 44 matching drugs for PSMB5 — including drugs targeting any of its 32 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
bortezomib PSMB5 Direct 2
avastin, bortezomib PSMB5 Direct 1
bortezomib, carboplatin, paclitaxel PSMB5 Direct 1
bortezomib, gemcitabine hydrochloride PSMB5 Direct 1
bortezomib, irinotecan PSMB5 Direct 1
bortezomib, radiation therapy PSMB5 Direct 1
bortezomib, temozolomide, pharmacological study PSMB5 Direct 1
carfilzomib PSMB5 Direct yes 1
cetuximab, bortezomib PSMB5 Direct 1
tamoxifen citrate, bortezomib PSMB5 Direct 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis PSMB5 Direct 1
vorinostat, therapeutic conventional surgery, bortezomib PSMB5 Direct 1
ixazomib PSMB5 Direct yes 0
ixazomib citrate PSMB5 Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan ATR SSL via ATR 1
carfilzomib PSMB8 SSL via PSMB8 yes 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
ceralasertib, olaparib, durvalumab ATR SSL via ATR 1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib ATR SSL via ATR 1
afatinib dimaleate EGFR SSL via EGFR yes 0
cetuximab EGFR SSL via EGFR yes 0
clofarabine POLD1 SSL via POLD1 yes 0
erlotinib hydrochloride EGFR SSL via EGFR yes 0
gemcitabine POLD1 SSL via POLD1 yes 0
gemcitabine hydrochloride POLD1 SSL via POLD1 yes 0
ixazomib PSMB8 SSL via PSMB8 yes 0
ixazomib citrate PSMB8 SSL via PSMB8 yes 0
lapatinib EGFR SSL via EGFR yes 0
lapatinib ditosylate EGFR SSL via EGFR yes 0
necitumumab EGFR SSL via EGFR yes 0
neratinib EGFR SSL via EGFR yes 0
neratinib maleate EGFR SSL via EGFR yes 0
osimertinib mesylate EGFR SSL via EGFR yes 0
panitumumab EGFR SSL via EGFR yes 0
regorafenib EGFR SSL via EGFR yes 0
vandetanib EGFR SSL via EGFR yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.